How can cfONCO- Colon help you？
Oxford offers you cfONCO- Colon non-invasive test through next generation screening technology, to test the mutation of colon cancer (including the latest SNP highly relate with the colon cancer.) It is also provided with targeted drugs recommendation approved by FDA, assisted treatment alternatives, post-treatment monitoring and evaluation of targeted drugs, early detection of drugs resistance in cancer targeted treatment. 
 
 Highlight: 
  • Non-Invasive- provide an alternative to sbustitue for colon cancer tissue sample and senior patients as well. Only a tube of plasma sample is valid for the test. The volume of cfDNA test is different for each patient, and the least volume is only 1 ng.
  • Low limit of detection- Enable variant detection down to 0.1%, with 90% sensitivity and >98% specificity for SNV hoptspots and indels.
  • High value content-  more than 235 hotspots, including KRAS G12/13 mutation, BRAF V600E etc.
  • Enable tumor heterogeneity- A breakthrough of heterogeous cancer cells which might cause drugs resisistance. ctDNA test helps to monitor somatic mutation from time to time. 
 
cfONCO- Colon
Content
AKT1, BRAF, CTNNB1, EGFR, ERBB2, FBXW7, GNAS, KRAS, MAP2K1, NRAS, PIK3CA, SMAD4, TP53, and APC
> 235 hotspots
SNVs and INDELs  including:
KRAS/NRAS: G12/G13/Q61、BRAF: V600E、PIK3CA: E545K, H1047R、TP53: R175H R273H/C/L、Recurrent deleterious APC mutations (including p.R876*, p.R1114*, p.Q1378*, and p.R1450*)、SMAD4: R361C/H、CTNNB1: S45F, T41A
Technology
Next Generation Sequencing
Participants
Primary Colon cancer
Substitute for colon cancer tissue sample
Senior patients
Significance
ctDNA test helps to monitor somatic mutation from time to time. 
Concept of Analysis
The results of screening will compare with Human Genome version 19 (hg19). The drug database provides FDA-approved cancer target drugs.
* please call or email if you need more information